The biotechnology company Inbiomotion, a member of Catalonia.health, has announced the publication, in the journal Journal of Medical Economics, of a study highlighting the positive economic impact of its diagnostic tool MAF Test® in patients with early-stage breast cancer.

The study demonstrates how the MAF Test®, which stratifies early-stage breast cancer patients by MAF gene status to guide adjuvant bisphosphonate therapy, delivers meaningful economic value across multiple healthcare systems.

Also, it concludes that the use of the test could save up to €105 million over ten years, thanks to improved patient stratification and a reduction in relapses. Moreover, it estimates an average saving of €2,732 per postmenopausal patient and €2,150 per premenopausal patient, with most of the benefits concentrated in the first five years.

The results strengthen the strategy of biomarker-based precision oncology, which optimizes the use of bisphosphonates only in cases with the highest likelihood of a positive response.

Ralf van den Berg, Chief Operating Officer of Inbiomotion, affirms: “With this new evidence, the MAF Test® consolidates its position as an indispensable tool for oncologists and healthcare systems, as it combines improved clinical outcomes with clear cost-efficiency”.

Since its launch in 2023, the MAF Test® has expanded its international adoption and, since July 2025, has been available in leading Spanish hospitals such as Hospital del Mar, Clínic Barcelona, both of the members of Catalonia.health, HM Hospitales, and IBCC/Pangaea Oncology, with a potential reach of 80% of the 33,000 early-stage breast cancer patients diagnosed annually in the country.